摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5beta,6beta,17alpha,22R)-5,6-环氧-14,17,20,22-四羟基-1-氧代-麦角甾-2,24-二烯-26-酸 delta-内酯 | 38254-15-8

中文名称
(5beta,6beta,17alpha,22R)-5,6-环氧-14,17,20,22-四羟基-1-氧代-麦角甾-2,24-二烯-26-酸 delta-内酯
中文别名
(5beta,6beta,17alpha,22R)-5,6-环氧-14,17,20,22-四羟基-1-氧代-麦角甾-2,24-二烯-26-酸delta-内酯
英文名称
(+)-withanolide E
英文别名
Withanolide E;(1S,2R,7S,9R,11R,12R,15S,16S)-15-[(1S)-1-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-1-hydroxyethyl]-12,15-dihydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-4-en-3-one
(5beta,6beta,17alpha,22R)-5,6-环氧-14,17,20,22-四羟基-1-氧代-麦角甾-2,24-二烯-26-酸 delta-内酯化学式
CAS
38254-15-8
化学式
C28H38O7
mdl
——
分子量
486.606
InChiKey
RUVPNJSJTWTANE-LFCBYZEKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    35
  • 可旋转键数:
    2
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.79
  • 拓扑面积:
    117
  • 氢给体数:
    3
  • 氢受体数:
    7

SDS

SDS:4da10d758af3bb702c6bb10438361709
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF APOPTOSIS INDUCING LIGANDS IN CANCER TREATMENT<br/>[FR] MÉTHODE DE SENSIBILISATION DE CELLULES CANCÉREUSES AUX EFFETS CYTOTOXIQUES DE LIGANDS INDUISANT L'APOPTOSE DANS LE TRAITEMENT DU CANCER
    申请人:US HEALTH
    公开号:WO2017139485A1
    公开(公告)日:2017-08-17
    Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, which method comprises contacting the cancer cells with an apoptosis inducing ligand in conjunction with an effective amount of a compound of the formula: (I), wherein R1-R14 are as described herein. Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with the compound described herein and also contacting the cancer cells with an apoptosis inducing ligand, whereby apoptosis is induced in the cancer cells.
    本发明公开了一种增强哺乳动物中癌细胞对凋亡诱导配体治疗反应的方法,该方法包括与式(I)化合物的有效量一起接触癌细胞和凋亡诱导配体,其中R1-R14如本文所述。本发明还公开了一种在哺乳动物中诱导癌细胞凋亡的方法,包括与本文所述化合物接触癌细胞,并且与凋亡诱导配体接触癌细胞,从而诱导癌细胞凋亡。
  • COMPOSITIONS FOR RECOVERING HYPOFERTILITY
    申请人:Nippon Shinyaku Co., Ltd.
    公开号:EP1208845A1
    公开(公告)日:2002-05-29
    The object of the present invention is to redress or relieve the effects of in vivo contaminations with endocrine disturbing chemicals and, as such, provide a composition and a food for promoting recovery of the reproductive function compromised by such chemicals. The present invention encompasses a composition for restoring compromised reproductive, characterized in that it comprises Withania somnifera.
    本发明的目的是纠正或缓解内分泌干扰化学物质的体内污染影响,并因此提供一种组合物和一种食品,用于促进受此类化学物质影响的生殖功能的恢复。 本发明包括一种用于恢复受损生殖功能的组合物,其特征在于该组合物由睡茄(Withania somnifera)组成。
  • AGENTS FOR MODULATION OF WNT-TCF SIGNALLING AND USES THEREOF
    申请人:UNIVERSITE DE GENEVE
    公开号:EP3248604A1
    公开(公告)日:2017-11-29
    The present invention relates to inhibitors of WNT-TCF signalling and compositions thereof. The invention further relates to use of those inhibitors of WNT-TCF signalling and compositions thereof for the treatment and/or prevention and/or prevention of recurrence of a WNT-activated cancer and/or a cancer associated with the cancer stem cells. the active compounds are certain cardenolides and bufanolides.
    本发明涉及WNT-TCF信号的抑制剂及其组合物。本发明还涉及将这些 WNT-TCF 信号抑制剂及其组合物用于治疗和/或预防和/或防止 WNT 激活的癌症和/或与癌症干细胞相关的癌症复发。
  • Methods for diagnosis and treatment of amyotrophic lateral sclerosis based on an increased level of interaction between TDP-43 polypeptide and NF-KB P65 polypeptide
    申请人:UNIVERSITE LAVAL
    公开号:US10060933B2
    公开(公告)日:2018-08-28
    The present invention provides methods and uses for the diagnostic of a subject predisposed or suspected of developing a neurodegenerative disease or suffering from a neurodegenerative disease. The present invention also relates to methods and uses for identifying candidate compounds and to compounds for treating neurodegenerative disease. The present invention also relates to an animal model for neurodegenerative disease.
    本发明提供了诊断易患或疑似易患神经退行性疾病或患有神经退行性疾病的受试者的方法和用途。本发明还涉及鉴定候选化合物和治疗神经退行性疾病的化合物的方法和用途。本发明还涉及神经退行性疾病的动物模型。
  • Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
    申请人:The United States of America, as represented by the Secretary, Department of Health and Human Services
    公开号:US10849912B2
    公开(公告)日:2020-12-01
    Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, which method comprises contacting the cancer cells with an apoptosis inducing ligand in conjunction with an effective amount of a compound of the formula: (I), wherein R1-R14 are as described herein. Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with the compound described herein and also contacting the cancer cells with an apoptosis inducing ligand, whereby apoptosis is induced in the cancer cells.
    本发明公开了一种增强哺乳动物体内癌细胞对凋亡诱导配体治疗反应的方法,该方法包括使癌细胞与凋亡诱导配体以及有效量的式化合物接触:(I),其中 R1-R14 如本文所述。还公开了一种诱导哺乳动物体内癌细胞凋亡的方法,包括使癌细胞与本文所述化合物接触,同时使癌细胞与凋亡诱导配体接触,从而诱导癌细胞凋亡。
查看更多